VBI Vaccines logo

VBI VaccinesNASDAQ: VBIV

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 April 2010

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
-vs. 3y high
-vs. sector
-vs. 3y high
-vs. sector
-vs. 3y high
-vs. sector
-vs. 3y high
-vs. sector

Dividend

No data over the past 3 years
$1.21 M$3.19 M
$1.21 M-$17.90 M

Analysts recommendations

Institutional Ownership

Included in screeners

No data

Similar companies

VBIV Latest News

VBI Vaccines' pan-coronavirus vaccine candidate produced broad protection against variants of concern
Market Watch27 September 2023 Sentiment: POSITIVE

VBI Vaccines Inc. said Wednesday the first clinical data from a Phase I trial of a pan-coronavirus vaccine candidate produced broad and durable protection against variants of concern.

Why Is VBI Vaccines (VBIV) Stock Down 40% Today?
InvestorPlace06 July 2023 Sentiment: NEGATIVE

VBI Vaccines (NASDAQ: VBIV ) stock is taking a beating on Thursday after the pharmaceutical company announced two stock offerings. VBI Vaccines announced both a public stock offering and a registered directing offering for shares of VBIV stock.

VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research15 May 2023 Sentiment: NEUTRAL

VBI Vaccines, Inc. (VBIV) came out with a quarterly loss of $2.43 per share versus the Zacks Consensus Estimate of a loss of $2.27. This compares to loss of $2.40 per share a year ago.

VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans
Zacks Investment Research05 April 2023 Sentiment: NEGATIVE

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split
Market Watch04 April 2023 Sentiment: NEGATIVE

VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct a reverse stock split. Cambridge, Mass.

What type of business is VBI Vaccines?

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

What sector is VBI Vaccines in?

VBI Vaccines is in the Healthcare sector

What industry is VBI Vaccines in?

VBI Vaccines is in the Biotechnology industry

What country is VBI Vaccines from?

VBI Vaccines is headquartered in United States

When did VBI Vaccines go public?

VBI Vaccines initial public offering (IPO) was on 26 April 2010

What is VBI Vaccines website?

https://www.vbivaccines.com

Is VBI Vaccines in the S&P 500?

No, VBI Vaccines is not included in the S&P 500 index

Is VBI Vaccines in the NASDAQ 100?

No, VBI Vaccines is not included in the NASDAQ 100 index

Is VBI Vaccines in the Dow Jones?

No, VBI Vaccines is not included in the Dow Jones index

When was VBI Vaccines the previous earnings report?

No data

When does VBI Vaccines earnings report?

Next earnings report date is not announced yet